Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA

References

• Kumar SK , RajkumarV, KyleRAet al. Multiple myeloma. Nat. Rev. Dis. Primers3, 17046 (2017).
   PubMed Web of Science ®Google Scholar
• Cowan AJ , AllenC, BaracAet al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol.4(9), 1221–1227 (2018).
   PubMed Web of Science ®Google Scholar
• van de Donk N , PawlynC, YongKL. Multiple myeloma. Lancet397(10272), 410–427 (2021).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Cancer Statistics Center: myeloma. ( Eds). (2022).
   Google Scholar
• Mikhael J . Treatment Options for Triple-class Refractory Multiple Myeloma. Clin. Lymphoma Myeloma Leuk20(1), 1–7 (2020).
   PubMed Web of Science ®Google Scholar
• Dhakal B , SzaboA, ChhabraSet al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol.4(3), 343–350 (2018).
   PubMed Web of Science ®Google Scholar
• Chakraborty R , HamiltonBK, HashmiSK, KumarSK, MajhailNS. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. Biol. Blood and Marrow Transplant.24(8), 1546–1553 (2018).
   PubMed Web of Science ®Google Scholar
• Gengenbach L , GrazianiG, ReinhardtHet al. Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. Cancers (Basel)13(17), (2021).
   PubMed Web of Science ®Google Scholar
• Gengenbach L , ReinhardtH, IhorstGet al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leuk. Lymphoma59(11), 2692–2699 (2018).
   PubMed Web of Science ®Google Scholar
• Mikhael J , IsmailaN, CheungMCet al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J. Clin. Oncol.37(14), 1228–1263 (2019).
   PubMed Web of Science ®Google Scholar
• Dima D , JiangD, SinghDJet al. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers14(17), 4082 (2022).
   PubMed Web of Science ®Google Scholar
• Pfizer . Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma (2022). Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy
   Google Scholar
• FDA . FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma (2022) Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
   Google Scholar
• Dimopoulos MA , MoreauP, TerposEet al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.32(3), 309–322 (2021).
   PubMed Web of Science ®Google Scholar
• Terpos E , MikhaelJ, HajekRet al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal11(2), 40 (2021).
   PubMed Web of Science ®Google Scholar
• Fifer SJ , HoKA, LybrandS, AxfordLJ, RoachS. Alignment of preferences in the treatment of multiple myeloma – a discrete choice experiment of patient, carer, physician, and nurse preferences. BMC Cancer20(1), 546 (2020).
   PubMed Web of Science ®Google Scholar
• Anderson P , BenfordM, HarrisN, KaravaliM, PiercyJ. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr. Med. Res. Opin.24(11), 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Babineaux SM , CurtisB, HolbrookT, MilliganG, PiercyJ. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open6(8), e010352 (2016).
   PubMed Web of Science ®Google Scholar
• Higgins V , PiercyJ, RoughleyAet al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr. Obes.9, 371–380 (2016).
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services . Oncology Care Model. Available from: https://innovation.cms.gov/innovation-models/oncology-care [Accessed November 2022]. ( Eds). (2022).
   Google Scholar
• Sonneveld P , Avet-LoiseauH, LonialSet al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood127(24), 2955–2962 (2016).
   PubMed Web of Science ®Google Scholar
• Yong K , DelforgeM, DriessenCet al. Multiple myeloma: patient outcomes in real-world practice. Br. J. Haematol.175(2), 252–264 (2016).
   PubMed Web of Science ®Google Scholar
• Wang PF , YeeCW, GorshBet al. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk. Lymphoma ( In press).
   Web of Science ®Google Scholar
• Gandhi UH , CornellRF, LakshmanAet al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia33(9), 2266–2275 (2019).
   PubMed Web of Science ®Google Scholar
• Batchelder L , PhilpottS, DivinoVet al. Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment. Future Oncol.18(25), 2843–2856 (2022).
   PubMed Web of Science ®Google Scholar
• Kazandjian D , LandgrenO. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin. Oncol.43(6), 682–689 (2016).
   PubMed Web of Science ®Google Scholar
• Janssens R , LangT, VallejoAet al. Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study. Front Med. (Lausanne)8, 686165 (2021).
   PubMed Web of Science ®Google Scholar